<DOC>
	<DOCNO>NCT00699491</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose IMC-A12 give together temsirolimus see well work treat patient locally recurrent metastatic breast cancer . Monoclonal antibody , cixutumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Giving IMC-A12 together temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Cixutumumab Temsirolimus Treating Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish recommend dose level cixutumumab temsirolimus phase II study patient metastatic breast cancer . ( Phase I ) II . To examine safety profile combination patient metastatic breast cancer . ( Phase I ) III . To assess anti-tumor activity ( term overall response rate ) toxicity profile cixutumumab combination temsirolimus patient metastatic breast cancer . ( Phase II ) SECONDARY OBJECTIVES : I . To estimate progression-free survival ( PFS ) overall survival distribution ( well 6-month PFS rate ) . II . To evaluate vivo mechanism action temsirolimus combination cixutumumab examine potential biomarker predictor treatment response . OUTLINE : This dose-escalation study cixutumumab . Patients receive temsirolimus IV 30 minute cixutumumab IV 60 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Peripheral blood sample collect periodically circulate marker mononuclear cell . Samples analyze pharmacodynamic assessment via western blot proteomic study . If pre-existing tumor tissue available , tissue examine immunohistochemical staining marker ( e.g. , pIRS-1 , pIGF-IR , pMAPK , pAKT [ S473 ] , pS6 , PTEN , Stathmin ) . Fluorescence situ hybridization use assess IGF-IR amplification . Gene resequencing perform identify mutation PIK3CA ( exon 9 20 ) , AKT1 , gene . Genes IGF-1 , IGF-II , IGFBP-1 , IGFBP-3 , others analyze reverse transcriptase-polymerase chain reaction . After completion study treatment , patient follow periodically 2 ( phase I ) 5 ( phase II ) year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm diagnosis breast cancer Metastatic locally recurrent disease ( locally recurrent disease stage IV [ e.g , chest wall involvement ] ) Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan ( phase II ) Must receive least 1 , 2 , prior chemotherapy regimen set metastatic locally recurrent ( stage IV chest wall involvement ) disease ( phase II ) No uncontrolled brain metastasis Brain metastasis permit study unless metastasis treat surgery radiotherapy , patient neurologically stable steroid ≥ 12 week ECOG performance status ( PS ) 01 OR Karnofsky PS 80100 % Life expectancy &gt; 12 week Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Absolute neutrophil count ≥ 1,500/μL Hemoglobin ≥ 8.5 g/dL Platelets ≥ 100,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN ( 5 time ULN LFT elevation due liver metastasis ) Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 60 mL/min Fasting serum cholesterol ≤ 350 mg/dL ( 9.0 mmol/L ) Fasting triglyceride ≤ 400 mg/dL ( 4.56 mmol/L ) Albumin ≥ 3.4 mg/dL Fasting serum glucose &lt; 120 mg/dL No baseline diabetes require oral hypoglycemics insulin ( phase I ) No poorly control diabetes mellitus ( phase II ) Patients history diabetes mellitus oral hypoglycemics insulin allow participate , provide fast blood glucose &lt; 120 mg/dL stable dietary therapeutic regimen condition No prior invasive nonbreast malignancy , except adequately treat basal cell squamous cell carcinoma skin cancer patient disease free ≥ 5 year No know hypersensitivity reaction macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) No allergic reaction attribute compound similar chemical biologic composition antiIGF1R recombinant monoclonal antibody IMCA12 temsirolimus Known HIVpositive patient CD4 count normal range eligible No uncontrolled intercurrent illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Uncontrolled symptomatic cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement No systemic anticancer therapy within past 3 week No radiotherapy within past 2 week No prior treatment agent target IGFIR/IGFs PI3K/Akt/mT OR pathway Any number prior therapy regimen allow ( phase I ) No concurrent hormonal agent use treatment breast cancer exception premenopausal woman gonadotrophinreleasing hormone ( GnRH ) agonist subsequently progress may , discretion treat physician , continue GnRH agonist No concurrent investigational agent herbal preparation No concurrent oral corticosteroid except replacement adrenal insufficiency No concurrent combination antiretroviral therapy HIVpositive patient No concurrent enzymeinducing antiepileptic drug ( EIAEDs ) ( e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inducer rifampin Hypericum perforatum ( St. John 's wort ) No concurrent chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>